A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses.
Several studies have shown that cell-mediated immune responses play a crucial role in controlling viral replication. As such, a candidate SARS vaccine should elicit broad CD8+ T-cell immune responses. Several groups of mice were immunized alone or in combination with SARS-nucleocapsid immunogen. A high level of specific SARS-CD8+ T-cell response was demonstrated in mice that received DNA encoding the SARS-nucleocapsid, protein and XIAP as an adjuvant. We also observed that co-administration of a plasmid expressing nucleocapsid, recombinant protein and montanide/CpG induces high antibody titers in immunized mice. Moreover, this vaccine approach merits further investigation as a potential candidate vaccine against SARS.
Azizi
Ali
A
Infectious Disease and Vaccine Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, K1H 8L1, Canada. aliazizi555@yahoo.ca
Aucoin
Susan
S
Tadesse
Helina
H
Frost
Rita
R
Ghorbani
Masoud
M
Soare
Catalina
C
Naas
Turaya
T
Diaz-Mitoma
Francisco
F